Status:
COMPLETED
Eosinophil and Anticoagulation in COVID-19 Patients
Lead Sponsor:
Bursa Postgraduate Hospital
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determin...
Eligibility Criteria
Inclusion
- Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH,
- agreed to participate in the study were included
Exclusion
- Patients with previous coagulopathy,
- continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease),
- glomerular filtration rate (GFR) \<30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.
Key Trial Info
Start Date :
May 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04507282
Start Date
May 15 2020
End Date
July 15 2020
Last Update
August 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bursa Yüksek İhtisas Hastanesi
Yıldırım, Turkey (Türkiye), 16310